Serial changes of the plasma prostanoids during myocardial ischemia-reperfusion in swine. Effects of magnesium, diltiazem, and a novel Mac-1 inhibitor

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 56, Issue 2, 1997, Pages 135-142

  Serebruany, V L ^a   Herzog, W R ^b   Gurbel, P A ^a  

^a UNION MEMORIAL HOSPITAL   (United States)

^b UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 OXOPROSTAGLANDIN F1 ALPHA; DILTIAZEM; MAGNESIUM; N (2,7 DIMETHYL 9 FLUORENYLMETHOXYCARBONYL)LEUCINE; PROSTANOID; THROMBOXANE B2;

ACUTE HEART INFARCTION; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; ENZYME IMMUNOASSAY; FEMALE; INTRAARTERIAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; REPERFUSION INJURY; STUNNED HEART MUSCLE; SWINE;

ANIMALIA; SUS SCROFA;

EID: 0031050975     PISSN: 09523278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-3278(97)90510-X     Document Type: Article

References (46)

1. 2 by coronary arteries after thrombolysis. Am Heart J 1993; 125: 277-284.
2. 2 release. Can J Physiol Pharm 1991; 69: 488-493.
3. Parratt J., Vegh A. Pronounced antiarrhythmic effects of ischemic preconditioning. Cardioscience 1994; 5: 9-18.
4. Corsi M., Parise M., Gaja G., Ferrero M. E. Possible role of defibrotide in endothelial cell protection. Int J Tiss React 1993; 15: 157-161.
5. Bolli R. Mechanism of myocardial 'stunning'. Circulation 1990; 82: 723-738.
6. Braunwald E., Kloner R. A. Myocardial reperfusion: A double edged sword? J Clin Invest 1985; 76: 1713-1719.
7. Bolli R. Myocardial stunning in man. Circulation 1992; 86: 1671-1691.
8. Braunwald E., Kloner R. A. The stunned myocardium: prolonged, post ischemic ventricular dysfunction. Circulation 1992; 66: 1146-1149.
9. Hearse D. J., Bolli R. Reperfusion induced injury: manifestations, mechanisms, and clinical relevance. Trends Cardiovasc Med 1991; 1: 233-240.
10. Lucchesi B. R. Myocardial ischemia., reperfusion and free radical injury. Am J Cardiol 1990; 65: 141-231.
11. Opie L. H. Reperfusion injury and its pharmacologic modification. Circulation 1989; 80: 1049-1062.
12. Woods K. L., Fletcher S. Long-term outcome after intravenous magnesium sulphate in suspected acute myocardial infarction: the second Leicester Intravenous Magnesium Intervention Trial (LIMIT-2). Lancet 1994; 343: 816-819.
13. ISIS-4: A randomized factorial trial assessing early oral captopril, oral mononitrate and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction. ISIS collaborative group. Lancet 1995; 345: 669-685.
14. Yusuf S. An overview of the clinical trials of agents (other than beta-blockers), that potentially limit myocardial infarct size. J Cardiovasc Pharm 1988: 12 (suppl. 1): S48-55.
15. Roberts R. Review of calcium antagonists trials in acute myocardial infarction. Clin Cardiol 1989; 12 (Suppl III): 4-47.
16. Kimura T., Yasue H., Sakaino N., Rokutanda M., Jougasaki M., Araki H. Effects of magnesium on the tone of isolated human coronary arteries. Circulation 1989; 79: 1118-1124.
17. Cho P. W., Gillinov A. M., Zehr K. J., Burch R. M., Winkelstein J. A., Cameron D. E. Neutrophil activation mediates protamine-induced pulmonary hypertension. J Surg Res 1993; 54: 486-493.
18. Bator J. M., Weitzberg M., Burch R. M. NPC 15669 prevents neutrophil adherence to endothelium and inhibits CD 11b/CD 18 upregulation. Immunopharmacology 1992; 23: 139-149.
19. Tanaka M., Brooks S. E., Richard V.J. et al Effect of anti-CD 18 antibody on myocardial neutrophil accumulation and infarct size after ischemia and reperfusion in dogs. Circulation 1993; 87: 526-535.
20. Herzog W. R., Gurbel P. A., Vogel R. A., Schlossberg M. L., Schneider A. I., Serebruany V. L. Effects of a novel leumedin NPC 15669 on myocardial stunning and preconditioned infarction size in swine. J Thromb Thrombolys 1995; 1: 163-170.
21. Friedman M., Wang S. Y., Sellke F. W., Cohn W. E., Weintraub R. M., Johnson R. G. Neutrophil adhesion blockade with NPC 15669 decreases pulmonary injury after total cardiopulmonary bypass. J Thromb Cardiovasc Surg 1996; 111: 460-468.
22. Serebruany V. L., Herzog W. R., Gurbel P. A., Schlossberg M. L., Scott H. J., Vogel R. A. NPC 15669, an antiinflammatory leucine derivate, reduces in vitro platelet aggregability in both swine and human plasma. J Thromb Thrombolys 1995; 1: 171-178.
23. Atar D., Serebruany V., Poulton J., Godard J., Schneider A., Herzog W. H. Effects of magnesium supplementation in a porcine model of myocardial ischemia and reperfusion. J Cardiovasc Pharm 1994; 24: 603-611.
24. Herzog W. R., Schlossberg M. L., MacMurdy K S. et al. Timing of magnesium therapy affects experimental infarct size. Circulation 1995; 92: 2622-2626.
25. Hohlfeld T., Strobach H., Schror K. Stimulation of endogenous prostacyclin protects the reperfused pig myocardium from ischemic injury. J Pharmacol Exp Ther 1993; 264: 397-405.
26. Yu C. L., Lin W. M., Liao T. S., Tsai C. Y., Sun K. H., Chen K. H. Tamm-Horsfall glycoprotein (THG) purified from normal human pregnancy urine increases phagocytosis, complement receptor expressions and arachidonic acid metabolism of polymorphonuclear neutrophils. Immunopharmacology 1992; 24: 181-190.
27. 2 in postischemic recovery of stunned canine myocardium. Circulation 1988; 78: 450-461.
28. Grover G. J. Thromboxane receptor blockade with SQ 30,741 improves post-ischemic myocardial function in anesthetized dogs. Proc Soc Exp Biol Med 1989; 192: 56-60.
29. Farber N. E., Gross G.J. Prostaglandin redirection by thromboxane synthetase inhibition. Attenuation of myocardial stunning in canine heart. Circulation 1990; 81: 369-380.
30. Laurant P., Moussard C., Albert D., Henry J. C., Berthelot A. In vivo and in vitro magnesium effects on aortic prostacyclin generation in DOCA-salt hypertensive rats. Prostaglandins Leukot Essent Fatty Acids 1992; 47: 183-186.
31. Pirich C., Schmid P., Fitscha P., Wytek R., O'Grady J., Sinzinger H. Influence of calcium antagonists on platelet function and vascular prostacyclin production. Blood Press 1994(S); 1: 75-80.
32. Nadler J. L., Goodson S., Rude R. K. Evidence that prostacyclin mediates the vascular action of magnesium in humans. Hypertension 1987; 9: 379-383.
33. Wilson T. W., Sharif M. N., Kaushal R. D. Diltiazem increases renal prostacyclin. Clin Invest Med 1991; 14: 596-599.
34. Yamada Y., Furui H., Furumichi T. et al Inhibitory effects of endothelial cells and calcium channel blockers on platelet aggregation. Jpn Heart J 1990; 31: 201-215.
35. Cremer K. F., Peiper J. A., Joyal M., Mehta J. Effects of diltiazem, dipyridamole, and their combination on hemostasis. Clin Pharm Ther 1984; 36: 641-644.
36. Takase B., Kurita A., Uehata A. et al Effect of diltiazem on silent ischemic episodes, plasma bradykinin and prostaglandin metabolism. Intern J Cardiol 1992; 37: 177-188.
37. 2 in patients with unstable angina pectoris treated with diltiazem or verapamil. Ugesk for Laeger 1992; 154: 3061-3063.
38. Riva C. M., Morganroth M. L., Ljungman A. G. et al. Iloprost inhibits neutrophil-induced lung injury and neutrophil adherence to endothelial monolayers. Am J Resp Cell Mol Biol 1990; 3: 301-309.
39. Ueno Y., Miyauchi Y., Nishio S. Beraprost sodium protects occlusion/reperfusion injury in the dog by inhibition of neutrophil migration. Gen Pharm 1994; 25: 427-432.
40. Sato N., Endo T., Kiuchi K., Hayakawa H. Effects of thromboxane synthetase inhibitor., Y-20811, on infarct size., neutrophil accumulation., and arrhythmias after coronary artery occlusion and reperfusion in dogs. J Cardiovasc Pharm 1993; 21: 353-361.
41. Kanayama T., Kimura Y., Mizogami S. A new prostacyclin analog, KP-10614, inhibits platelet-polymorphonuclear leukocyte interaction and limits experimental infarct size in rat heart. J Pharmacol Exp Ther 1993; 266: 344-349.
42. 2 analogue, sodium beraprost, suppresses Superoxide generation in human neutrophils by inhibiting p47phox phosphorylation. Life Sci 1995; 57: 1051-1059.
43. Ruf A., Patcheke H. Platelet-induced neutrophil activation: platelet-expressed fibrinogen induces the oxidative burst in neutrophils by an interaction with CD11/CD18. Br J Haemat 1995; 90: 791-796.
44. Fedor J. L., McIntosh D. M., Rembert J. C., Greenfield J. C. Coronary and transmural myocardial blood flow responses in awake domestic pigs. Am J Physiol 1978; 235: H435-444.
45. Softeland E., Framstad T., Thorsen T., Holmsen H. Porcine platelets in vitro and in vivo studies: Relevance to human thrombosis research. Eur J Haematol 1992; 49: 161-173.
46. Yao S. K., Ober J. C., Gonenne A. Active oxygen species play a role in mediating platelet aggregation and cyclic flow variations in severely stenosed and endothelium-injured coronary arteries. Circ Res 1993; 73: 952-967.